Literature DB >> 2539325

Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis.

M A Cassatella1, G Berton, C Agostini, R Zambello, L Trentin, A Cipriani, G Semenzato.   

Abstract

We studied superoxide anion (O2) generation by alveolar macrophages (AM) isolated from bronchoalveolar lavages (BAL) of patients with sarcoidosis, and assayed immediately after the isolation or after maintenance in culture for 2 days. In assays of cells freshly isolated from BAL, AM of patients with active sarcoidosis with a high-intensity lymphocytic alveolitis produced more O2- in response to phorbol myristate acetate than AM of patients with inactive sarcoidosis. Also, after 2 days of cultivation sarcoid AM were heterogeneous in their capability to metabolize oxygen, although both AM of active and inactive sarcoid patients produced higher amounts of O2- than AM of healthy subjects. In vitro treatment with recombinant interferon-gamma (rIFN-gamma) caused an enhancement of the capability of AM of inactive sarcoid patients to produce O2- in response to PMA. AM of patients with active sarcoidosis did not respond to rIFN-gamma when they already produced O2- vigorously. However, they became sensitive to the activating effect of rIFN-gamma after the down-modulation of their capability to produce O2-, that occurred upon prolonged cultivation. Monocytes isolated from blood of sarcoid patients and assayed immediately or after different times of cultivation did not produce more O2- than control monocytes and monocyte-derived macrophages, thus indicating that the activation of AM in sarcoidosis is likely a local phenomenon. These studies strengthen the notion that T lymphocyte-macrophage interaction is a critical event in the pathogenesis of sarcoidosis and establish that the enhanced capability to metabolize oxygen to highly reactive intermediates by AM is one of the consequence of this interaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539325      PMCID: PMC1385236     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3.

Authors:  A O Fels; C F Nathan; Z A Cohn
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

2.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

Review 3.  Pathogenesis of the granulomatous lung diseases.

Authors:  G W Hunninghake; K C Garrett; H B Richerson; J C Fantone; P A Ward; S I Rennard; P B Bitterman; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1984-09

4.  Recombinant human gamma-interferon induces human monocyte polykaryon formation.

Authors:  J B Weinberg; M M Hobbs; M A Misukonis
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

5.  Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response.

Authors:  M J Pabst; H B Hedegaard; R B Johnston
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

6.  Superoxide release by peritoneal and bone marrow-derived mouse macrophages. Modulation by adherence and cell activation.

Authors:  G Berton; S Gordon
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

7.  Characterization of mononuclear phagocyte subpopulations in the human lung by using monoclonal antibodies: changes in alveolar macrophage phenotype associated with pulmonary sarcoidosis.

Authors:  A J Hance; S Douches; R J Winchester; V J Ferrans; R G Crystal
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates.

Authors:  A Nakagawara; N M DeSantis; N Nogueira; C F Nathan
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

9.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

10.  Activation of human macrophages. Comparison of other cytokines with interferon-gamma.

Authors:  C F Nathan; T J Prendergast; M E Wiebe; E R Stanley; E Platzer; H G Remold; K Welte; B Y Rubin; H W Murray
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  6 in total

1.  Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE).

Authors:  H Groen; M Aslander; H Bootsma; T W van der Mark; C G Kallenberg; D S Postma
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

2.  Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up.

Authors:  Wojciech J Piotrowski; Zofia Kurmanowska; Adam Antczak; Jerzy Marczak; Paweł Górski
Journal:  BMC Pulm Med       Date:  2010-04-27       Impact factor: 3.317

3.  Exhaled 8-isoprostane in sarcoidosis: relation to superoxide anion production by bronchoalveolar lavage cells.

Authors:  Wojciech J Piotrowski; Zofia Kurmanowska; Adam Antczak; Jerzy Marczak; Maciej Ciebiada; Paweł Górski
Journal:  Inflamm Res       Date:  2010-06-03       Impact factor: 4.575

Review 4.  Cellular events in alveolitis and the evolution of pulmonary fibrosis.

Authors:  A Burkhardt; H Cottier
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

Review 5.  The Role of Oxidative Stress in Sarcoidosis.

Authors:  Sara Solveig Fois; Sara Canu; Alessandro Giuseppe Fois
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

6.  Novel protein pathways in development and progression of pulmonary sarcoidosis.

Authors:  Maneesh Bhargava; K J Viken; B Barkes; T J Griffin; M Gillespie; P D Jagtap; R Sajulga; E J Peterson; H E Dincer; L Li; C I Restrepo; B P O'Connor; T E Fingerlin; D M Perlman; L A Maier
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.